SULT1A1 Arg213his polymorphism and lung cancer risk: A meta-analysis

Asian Pacific Journal of Cancer Prevention

Volumn 13, Issue 2, 2012, Pages 579-583

  Liao, Shao Guang ^a   Liu, Lu ^a   Zhang, Ying Yi ^a   Wang, Ying ^a   Wang, Ya Jie ^a  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Genetic polymorphisms; Lung cancer; Meta analysis; SULT1A1

Indexed keywords

ARYL SULFOTRANSFERASE; SULT1A1 PROTEIN, HUMAN; TUMOR MARKER;

ARTICLE; CASE CONTROL STUDY; FEMALE; GENETIC POLYMORPHISM; GENETICS; HUMAN; LUNG TUMOR; MALE; MORTALITY; PATHOLOGY; PROGNOSIS; RISK FACTOR;

ARYLSULFOTRANSFERASE; CASE-CONTROL STUDIES; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; POLYMORPHISM, GENETIC; PROGNOSIS; RISK FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 84866449777     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: 10.7314/APJCP.2012.13.2.579     Document Type: Article

References (32)

1. Arlt VM, Glatt H, Muckel E, et al (2002). Metabolic activation of the environmental contaminant 3-nitrobenzanthrone by humanacetyltransferases and sulfotransferase. Carcinogenesis, 23, 1937-45.
2. Arslan S, Silig Y, Pinarbasi H (2009). An investigation of the relationship between SULT1A1 Arg(213) his polymorphism and lung cancersusceptibility in a Turkish population. Cell Biochem Funct, 27, 211-5.
3. Bardakci F, Arslan S, Bardakci S, et al (2008). Sulfotransferase 1A1 (SULT1A1) polymorphism and susceptibility to primary brain tumors. J Cancer Res Clin Oncol, 134, 109-14.
4. Cochran WG (1954). The combination of estimates from different experiments. Biometrics, 10, 101-29.
5. Chou HC, Lang NP, Kadlubar FF (1995). Metabolic activation of the N-hydroxy derivative of the carcinogen 4-aminobiphenyl by human tissue sulfotransferases. Carcinogenesis, 16, 413-7.
6. Coughtrie MW, Gilissen RA, Shek B, et al (1999). Phenol sulphotransferase SULT1A1 polymorphism: molecular diagnosis and allele frequencies in Caucasian and African populations. Biochem J, 337, 45-9.
7. DerSimonian R, Laird N (1986). Meta-analysis in clinical trials. Control Clin Trials, 7, 177-88.
8. Egger M, Davey Smith G, Schneider M, et al (1997). Bias in meta-analysis detected by a simple, graphical test. BMJ, 315, 629-34.
9. Falany CN (1997). Enzymology of human cytosolic sulfotransferases. FASEB J, 11, 206-16.
10. Greenlee RT, Murray T, Bolden S, et al (2000). Cancer statistics. CA Cancer J Clin, 50, 7-33.
11. Hecht SS (1999). DNA adduct formation from tobacco-specific N-nitrosamines. Mutat Res, 424, 127-42.
12. Han DF, Zhou X, Hu MB, et al (2004). Sulfotransferase 1A1 (SULT1A1) polymorphism and breast cancer risk in Chinese women. Toxicol Lett, 150, 167-77.
13. Hirata H, Hinoda Y, Okayama N, et al (2008). CYP1A1, SULT1A1, and SULT1E1 polymorphisms are risk factors for endometrial cancer susceptibility. Cancer, 112, 1964-73.
14. Jiang Y, Zhou L, Yan T, et al (2010). Association of sulfotransferase SULT1A1 with breast cancer risk: a meta-analysis of case-control studies with subgroups of ethnic and menopausal statue. J Exp Clin Cancer Res, 29, 101.
15. Liang G, Miao X, Zhou Y, et al (2004). A functional polymorphism in the SULT1A1 gene (G638A) is associated with risk of lung cancer in relation to tobacco smoking. Carcinogenesis, 25, 773-8.
16. MANTEL N, HAENSZEL W (1959). Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst, 22, 719-48.
17. Nowell S, Ratnasinghe DL, Ambrosone CB, et al (2004). Association of SULT1A1 phenotype and genotype with prostate cancer risk in African-Americans and Caucasians. Cancer Epidemiol Biomarkers Prev, 13, 270-6.
18. Ozawa S, Chou HC, Kadlubar FF, et al (1994). Activation of 2-hydroxyamino-1-methyl-6-phenylimidazo[4,5-b] pyridine by cDNA-expressed human and rat arylsulfotransferases. Jpn J Cancer Res, 85, 1220-8.
19. Ozawa S, Tang YM, Yamazoe Y, et al (1998). Genetic polymorphisms in human liver phenol sulfotransferases involved in the bioactivation of N-hydroxy derivatives of carcinogenic arylamines and heterocyclic amines. Chem Biol Interact, 109, 237-48.
20. Pachouri SS, Sobti RC, Kaur P, et al (2006). Impact of polymorphism in sulfotransferase gene on the risk of lung cancer. Cancer Genet Cytogenet, 171, 39-43.
21. Raftogianis RB, Wood TC, Otterness DM, et al (1997). Phenol sulfotransferase pharmacogenetics in humans: association of common SULT1A1 alleleswith TS PST phenotype. Biochem Biophys Res Commun, 239, 298-304.
22. Raftogianis RB, Wood TC, Weinshilboum RM (1999). Human phenol sulfotransferases SULT1A2 and SULT1A1: genetic polymorphisms, allozyme properties, and human liver genotype-phenotype correlations. Biochem Pharmacol, 58, 605-16.
23. Richard K, Hume R, Kaptein E, et al (2001). Sulfation of thyroid hormone and dopamine during human development: ontogeny of phenol sulfotransferases and arylsulfatase in liver, lung, and brain. J Clin Endocrinol Metab, 86, 2734-42.
24. Shopland DR, Eyre HJ, Pechacek TF (1991). Smoking-attributable cancer mortality in 1991: is lung cancer now the leading cause of deathamong smokers in the United States?. J Natl Cancer Inst, 83, 1142-8.
25. Surh YJ, Tannenbaum SR (1995). Sulfotransferase-mediated activation of 7,8,9,10-tetrahydro-7-ol, 7,8-dihydrodiol, and 7,8,9,10-tetraol derivatives of benzo[a]pyrene. Chem Res Toxicol, 8, 693-8.
26. Sun Y, Zang Z, Xu X, et al (2011). The association of SULT1A1 codon 213 polymorphism and breast cancer susceptibility: meta-analysis from 16 studies involving 23,445 subjects. Breast Cancer Res Treat, 125, 215-9.
27. Tamaki Y, Arai T, Sugimura H, et al (2011). Association between cancer risk and drug-metabolizing enzyme gene (CYP2A6, CYP2A13, CYP4B1, SULT1A1, GSTM1, and GSTT1) polymorphisms in cases of lung cancer in Japan. Drug Metab Pharmacokinet, 26, 516-22.
28. Watabe T, Ishizuka T, Isobe M, et al (1982). A 7-hydroxymethyl sulfate ester as an active metabolite of 7,12-dimethylbenz[alpha]anthracene. Science, 215, 403-5.
29. Wang Y, Spitz MR, Tsou AM, et al (2002). Sulfotransferase (SULT) 1A1 polymorphism as a predisposition factor for lung cancer: a case-control analysis. Lung Cancer, 35, 137-42.
30. Wong CF, Liyou N, Leggett B, et al (2002). Association of the SULT1A1 R213H polymorphism with colorectal cancer. Clin Exp Pharmacol Physiol, 29, 754-8.
31. Wang LQ, James MO (2005). Sulfotransferase 2A1 forms estradiol-17-sulfate and celecoxib switches the dominant product fromestradiol-3-sulfate to estradiol-17-sulfate. J Steroid Biochem Mol Biol, 96, 367-74.
32. Wang Z, Fu Y, Tang C, et al (2010). SULT1A1 R213H polymorphism and breast cancer risk: a meta-analysis based on 8,454 cases and 11,800 controls. Breast Cancer Res Treat, 122, 193-8.